Information  X 
Enter a valid email address

BioProgress PLC (MDX)

  Print      Mail a friend

Wednesday 04 August, 2004

BioProgress PLC

Appointment of JP Morgan

BioProgress PLC
04 August 2004

Press Release                                                     04 August 2004

                               BioProgress plc

                       ('BioProgress' or 'the Company')

              BioProgress appoints JPMorgan for US Nasdaq listing

Further to the announcement made by BioProgress plc, a provider of innovative
delivery mechanisms for the pharmaceutical oral dosage markets, on 10 June 2004,
the Company is now pleased to announce that JPMorgan Chase Bank has been
appointed as the US depositary for BioProgress' listing of its Ordinary Shares
in the form of American Depositary Receipts (ADRs) on the NASDAQ National Market
in the USA.

The Board of Directors of the Company have decided to apply to list ADRs
representing Ordinary Shares of the Company on the NASDAQ National Market and
entry onto this market is likely to take place during the third week of

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  This announcement contains certain 'forward-looking
statements' within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements are based on management's current expectations and are
subject to uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking statements.
The forward-looking statements in this release include statements addressing
future financial and operating results and the timing and benefits of the
reorganization. Detailed information about factors pertinent to the business of
the company that could cause actual results to differ is set forth in the
Company's filings with the Securities and Exchange Commission. The Company is
under no obligation to (and expressly disclaim any such obligation to) update or
alter its forward-looking statements whether as a result of new information,
future events or otherwise.

                                    - Ends -

For further information:
  BioProgress plc
  Graham Hind, Chief Executive                         Tel: +44 (0) 1354 655 674                       

Media enquiries:
  Henry Harrison-Topham / Heather Salmond              Tel: +44 (0) 20 7398 7700                   

Notes to editors:

BioProgress listed on AIM in May 2003 and is engaged in the research,
development, and design of patented encapsulation systems that use water soluble
and biodegradable films for the dietary supplement, pharmaceutical and other
sectors. The Company's patent portfolio comprises over sixty patents within
sixteen patent families and has product development agreements and strategic
alliances with several global companies.  BioProgress aims to provide a cost
effective and animal-free encapsulation process for pharmaceutical drugs in
liquids, tablets and powders, thereby addressing the needs of the entire market
for oral dosage forms while providing novel delivery mechanisms not possible
with traditional processes.

The Company has also developed patented and licensed the world's first flushable
ostomy pouch that offers a newly enhanced quality of life not previously
possible for the end user. Market research shows the global ostomy market to be
worth $1 billion annually.

The Company's business model provides it with several significant revenue
streams including sales of encapsulating machines and film, plus licence and
fees for research development services.

                      This information is provided by RNS
            The company news service from the London Stock Exchange